Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • BioCryst Pharmaceuticals Inc.
  • Dynavax Technologies Corp.
  • Galectin Therapeutics Inc.
  • Galmed Pharmaceuticals Ltd.
  • Immune Pharmaceuticals Inc.
  • NeoStem Inc.
  • Pluristem Therapeutics Inc.
  • Tenax Therapeutics Inc.

Vernon Bernardino

MLV & Co

Image: Vernon Bernardino

Vernon Bernardino is an analyst in MLV & Co.'s life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.




Recent Interviews

Biotechs with Upside Possibilities Target Ebola and Liver Disease: MLV & Co.'s Vernon Bernardino (9/10/14) Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where a number of players are developing products. In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.

Not All Stem Cells Are Created Equal: Vernon Bernardino (10/3/13) Biotech companies are fiercely competing to create the newest and best miracle drugs using stem cell technologies. How can an investor spot the potentially victorious outliers amid the chaos of rival scientific claims? The failure rate of new product development in the only recently understood cell space is terrifying, but in this interview with The Life Sciences Report, analyst Vernon Bernardino of MLV & Co. reveals his formula for evaluating the strongest contenders. Bernardino also names five companies with products that may succeed in this new and competitive space.

Recent Quotes

"We remain positive and believe NBS10 will advance." (11/18/14) NeoStem Inc. - Vernon Bernardino, MLV & Co More >

"NBS's NBS10 could achieve a peak of 29% share of STEMI patients receiving coronary stents." (11/14/14) NeoStem Inc. - Vernon Bernardino, MLV & Co More >

"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

"IMNP's bertilimumab is a powerful antibody." (9/10/14) Immune Pharmaceuticals Inc. - The Life Sciences Report Interview with Vernon Bernardino More >

"We are expecting a catalyst-rich 2014 for PSTI." (2/6/14) Pluristem Therapeutics Inc. - Vernon Bernardino, MLV & Co More >

"A partnership for IMNP's NanomAbs could garner $50M up front and $175–250M overall." (1/27/14) Immune Pharmaceuticals Inc. - Vernon Bernardino, MLV & Co More >

"NBS obtained IP status for its specific stem cell therapy, making it more commercially viable." (10/3/13) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >



Due to permission requirements, not all quotes are shown.